Nebraska providers have begun offering a new treatment for uveal melanoma that has metastasized to the liver, the Lincoln Journal Star reports. The therapy targets a rare cancer that starts in the eye and, in advanced cases, spreads hepatically.

The condition is uncommon. Uveal melanoma differs from cutaneous melanoma, and liver metastasis remains its dominant site of distant spread. The new Nebraska program gives patients in the region a local option rather than travel to distant centers.

Why liver metastasis drives treatment decisions?

Ocular melanoma behaves differently from skin melanoma, and its hepatic spread has historically limited systemic options. Nebraska clinicians now report a treatment aimed specifically at this metastatic pattern, per the Journal Star.

Details on trial endpoints, patient numbers and manufacturer data weren't included in the initial report. Derm Field will follow the story as fuller clinical information emerges from the Nebraska program.